Syra Health Corp. Class A Common Stock
SYRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.06 | 0.16 | -0.07 |
| FCF Yield | 0.00% | -5.57% | 8.38% | -7.18% |
| EV / EBITDA | 7.51 | 16.66 | 1.02 | -2.13 |
| Quality | ||||
| ROIC | -9.51% | -2.50% | -18.30% | -15.07% |
| Gross Margin | 32.85% | 38.69% | 31.71% | 22.69% |
| Cash Conversion Ratio | -0.47 | 1.14 | -0.34 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.48% | 12.61% | 11.33% | 12.42% |
| Free Cash Flow Growth | -40.82% | -145.80% | 173.69% | 48.05% |
| Safety | ||||
| Net Debt / EBITDA | 7.51 | 40.87 | 5.11 | 3.95 |
| Interest Coverage | 0.00 | -16.37 | -146.59 | -90.75 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 24.18 | -1.02 | 22.76 | 24.64 |